Metgen (Metoclopramide Hydrochloride Monohydrate)

Metoclopramide, the active ingredient in Metgen, is a dopamine antagonist (antiemetic) presented as an oral tablet for oral use. It is employed to relieve nausea and vomiting, improve gastric emptying in gastroparesis, and manage reflux esophagitis and chemotherapy‑induced nausea.

GNH USA supplies Metgen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assured manufacturing, regulatory approvals across the EU, and a dedicated logistics network for timely delivery. The company also provides technical support and documentation to meet local regulatory requirements.

Metoclopramide is used to treat disorders of the gastrointestinal tract and the central emetic pathways. - Nausea and vomiting: reduces episodes by blocking dopamine receptors in the chemoreceptor trigger zone. - Gastroparesis: enhances gastric motility and accelerates emptying to improve symptoms. - Reflux esophagitis: increases lower esophageal sphincter tone and promotes gastric clearance, reducing reflux episodes. - Chemotherapy‑induced nausea: prevents or lessens nausea associated with cytotoxic agents by antagonizing central dopamine pathways.

Metoclopramide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Restlessness or anxiety: mild agitation or nervousness. - Diarrhea: loose or frequent stools. - Dry mouth: reduced salivation causing discomfort. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Extrapyramidal symptoms: muscle rigidity, tremor, or involuntary movements. - Tardive dyskinesia: persistent, potentially irreversible facial or limb movements. - Neuroleptic malignant syndrome: rare but life‑threatening hyperthermia and muscle breakdown. - Severe depression or suicidal thoughts. - Cardiac arrhythmias: irregular heart rhythm, especially in patients with underlying heart disease.

Before prescribing Metgen, clinicians should consider several safety measures. - Assess patient history: screen for Parkinson's disease, seizure disorders, or depression. - Monitor for extrapyramidal symptoms: observe for muscle rigidity, tremor, or involuntary movements. - Limit duration: avoid use beyond 12 days unless medically justified. - Avoid in children under 1 year: contraindicated due to risk of severe side effects. - Pregnancy and lactation: use only if benefit outweighs risk; data are limited. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and light.

Metoclopramide can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increase metoclopramide plasma concentrations. - Anticholinergic agents: may reduce the prokinetic effect of metoclopramide. - Other dopamine antagonists (e.g., antipsychotics): additive risk of extrapyramidal symptoms.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines, alcohol): enhance sedation and drowsiness. - Macrolide antibiotics (e.g., erythromycin): may increase gastrointestinal motility synergistically. - Serotonergic agents (e.g., SSRIs): potential for serotonin syndrome when combined with other antiemetics.